Wuhan Wuyao Pharmaceutical Co.,Ltd.

EP

20190404-211-J-331

• (+)-2,2'-(ethylenediimino)di-1-butanol
• (+)-ethambutol
• (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine
• (+)-S,S-ethambutol
• (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol
• (S,S)-ethambutol

An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)

74-55-5

If you need more information, please contact us.

Mylan Laboratories Limited

In-house

20190220-209-J-133

5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine

5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl

5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine

Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

202409-33-4

If you need more information, please contact us.